Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Cerebral Infarction
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Zontivity
Zontivityis indicated for the reduction of atherothrombotic events in adult patients with a history of myocardial infarction (MI), ,co-administered with acetylsalicylic acid (ASA) and, where appropriate, clopidogrel; or symptomatic peripheral arterial disease (PAD), co-administered with acetylsalicylic acid (ASA) or, where appropriate, clopidogrel.
View on EMADiabetic Retinopathy
Osteoporosis
Cardiovascular Disease
Malignant Neoplasms of Male Genital Organs
HPV Positive Oropharyngeal Squamous Cell Carcinoma